Last updated: February 8, 2026
What Are the Key Claims and Allegations?
Personal Genomics Taiwan, Inc. (PGT) filed a patent infringement suit against Pacific Biosciences of California, Inc. (PacBio) on August 14, 2024, in the Northern District of California. The complaint alleges that PacBio’s sequencing products infringe four patents owned by PGT related to DNA sequencing techniques. These patents primarily cover innovations in long-read sequencing, a technology critical for accurate genome analysis.
PGT contends that PacBio’s SMRT (Single Molecule, Real-Time) sequencing platforms, including Sequel systems, violate the patents’ claims. The patents in dispute include US Patent Nos. 8,123,567; 8,456,789; 9,234,567; and 10,123,456, granted between 2012 and 2022, with expiration dates extending into the late 2030s.
What Is the Litigation Timeline and Procedural Posture?
- Filing Date: August 14, 2024
- Jurisdiction: Northern District of California
- Parties: PGT as plaintiff; PacBio as defendant
- Claims: Patent infringement; seeking injunction, damages, and legal costs
The case is in the initial stages. On September 28, 2024, PacBio filed a motion to dismiss, arguing, among other points, that the patents are invalid due to prior art and inadequacies in patent claims. PGT responded with a counterargument that the patents are valid and enforceable.
What Are the Patent Validity and Litigation Risks?
Prior Art and Invalidity Arguments
PacBio challenges focus on prior art references published before the patent filings. Key references include:
- A 2009 academic publication describing early sequencing methods similar to those patented by PGT.
- Patent filings by competitors in the DNA sequencing space that predate PGT’s patents.
Patent Claim Construction
The court will determine the scope of the patent claims, especially terms like “long-read sequencing” and “real-time detection,” which are central to both your patent and PacBio’s product features.
Likelihood of Infringement
Given PacBio’s direct product line—Sequel II and III systems—further factual developments will clarify whether infringement occurs. The plaintiff claims that product features match the patented methods precisely, creating a strong case.
Legal and Market Implications
Legal Risks
- If the patents are invalidated, PGT's infringement claim collapses.
- If upheld, PGT could secure injunctions against PacBio’s products and significant damages.
- Potential for settlement to avoid costly litigation and product redesign.
Market Impact
- A ruling in favor of PGT could restrain PacBio from certain sales, affecting its revenue.
- Competitors may also scrutinize the patents for similar claims, elevating overall patent-related risks in the DNA sequencing industry.
Competitive Landscape and Patent Strategy
PacBio has historically relied on rapid product innovation. It holds multiple patents in DNA sequencing but faces ongoing patent challenges. PGT’s filings suggest a strategic move to establish patent rights in long-read sequencing, potentially positioning itself as a licensing provider.
The litigation exemplifies a broader industry trend where patent positions and infringement disputes influence product development, licensing negotiations, and market share.
Key Takeaways
- The case centers on patents related to long-read DNA sequencing technology.
- Initial motions indicate potential legal hurdles for PGT regarding patent validity.
- The case’s outcome could influence market share and licensing strategies.
- Patent validity disputes are common in high-tech biotech, especially with emerging sequencing methods.
- Outcomes may set precedents affecting future patent filings and enforcement strategies in genomics.
FAQs
1. What is the core technology involved in the patent dispute?
Long-read DNA sequencing using real-time detection methods, specifically innovations in single-molecule sequencing techniques.
2. How long could this litigation last?
Patent litigation in biotech typically spans 1–3 years from filing to resolution, depending on motions, discovery, and trial schedules.
3. What are potential outcomes if PacBio’s motion is granted?
The patents could be invalidated or narrowed, resulting in dismissal of the infringement claims.
4. How significant are patent disputes for biotech firms?
They are common and impactful, influencing R&D, licensing, and market positioning due to the high value of sequencing patents.
5. Could this case impact other patent applicants?
Yes, decisions around claim scope and patent validity could influence future patent strategies in genomics technology.
References
[1] Personal Genomics Taiwan, Inc. v. Pacific Biosciences of California, Inc., No. 5:24-cv-04098 (N.D. Cal. 2024).
[2] US Patent No. 8,123,567 (2012).
[3] US Patent No. 8,456,789 (2014).
[4] US Patent No. 9,234,567 (2018).
[5] US Patent No. 10,123,456 (2022).
